CIK 0000842023 · Large accelerated filer
BIO-TECHNE Corp
Sign in to watch- Ticker
- TECH
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jun 30
- Incorporated
- MN
- Entity type
- operating
- EIN
- 411427402
- Phone
- 612-379-8854
- Business address
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Former names
- TECHNE CORP /MN/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-08-07 | Hippel James Chief Financial Officer | Shares withheld for taxes | −1,094 | $180.14 | $197K | 4,382 |
| 2018-08-07 | Hippel James Chief Financial Officer | Option exercise · Restricted Stock Units | −2,398 | 602 | ||
| 2018-08-07 | Hippel James Chief Financial Officer | Returned to the company · Restricted Stock Units | −602 | 0 | ||
| 2018-08-07 | Hippel James Chief Financial Officer | Returned to the company · Stock Options (Right to buy) | −3,762 | 14,988 | ||
| 2018-06-07 | Kummeth Charles R. Chief Executive Officer | Sale | −8,000 | $160.00 | $1.3M | 76,472 |
| 2018-05-04 | Eansor Norman David SVP - Novus Biologicals | Sale | −1,136 | $145.19 | $165K | 2,266 |
| 2018-05-01 | Kelderman Kim President, Diagnostics & Genom | Grant or award · Restricted Stock | +5,000 | 5,000 | ||
| 2018-05-01 | Kelderman Kim President, Diagnostics & Genom | Grant or award · Stock Option (Right to Buy) | +2,652 | 2,652 | ||
| 2018-05-01 | Kelderman Kim President, Diagnostics & Genom | Grant or award · Stock Option (Right to Buy) | +7,348 | 10,000 | ||
| 2018-02-13 | Dinarello Charles A Director | Option exercise | +5,000 | $65.47 | $327K | 13,212 |
| 2018-02-13 | Dinarello Charles A Director | Sale | −2,495 | $135.76 | $339K | 10,717 |
| 2018-02-13 | Dinarello Charles A Director | Sale | −2,505 | $136.36 | $342K | 8,212 |
| 2018-02-13 | Dinarello Charles A Director | Option exercise · Stock Option (right to buy) | −5,000 | 0 | ||
| 2017-11-01 | BAUMGARTNER ROBERT V Director | Option exercise | +5,000 | $63.03 | $315K | 12,712 |
| 2017-11-01 | BAUMGARTNER ROBERT V Director | Sale | −5,000 | $130.18 | $651K | 7,712 |
| 2017-11-01 | BAUMGARTNER ROBERT V Director | Option exercise · Stock Option (Right to buy) | −5,000 | 0 | ||
| 2017-10-26 | KEEGAN JOSEPH D Director | Grant or award | +739 | 739 | ||
| 2017-10-26 | KEEGAN JOSEPH D Director | Grant or award · Stock Options (Right to buy) | +3,125 | 3,125 | ||
| 2017-10-26 | Kummeth Charles R. Chief Executive Officer | Grant or award | +14,194 | 84,472 | ||
| 2017-10-26 | Kummeth Charles R. Chief Executive Officer | Grant or award · Restricted Stock Unit | +21,291 | 21,291 |
Page 56 of 64 · 1,274 trades